Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Worsley, A. Amour, A. Deans, I. McSherry, M. Lennon, S. Fung, N. Hamblin, P. Hawkins, E. M. Hessel (Stevenage, Cambridge, United Kingdom). The effect of a novel phosphoinositide 3-kinase Δ inhibitor (PI3KΔ), GSK2269557, on potential biomarkers measured from the lungs of healthy male smokers. Eur Respir J 2013; 42: Suppl. 57, 4859

Member's Comments

No comment yet.

Related content which might interest you: RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Inhibition of lung inflammation by a protein epitope mimetic (PEM) neutrophil elastase inhibitor, POL6014, in a sub-chronic tobacco smoke (TS) model in mice Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017 Systemic inhibition of p38 MAPK improves lung function and inflammatory markers in moderate-severe COPD Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 The effect of smoking on phosphoinositide 3-kinase (PI3K) and phosphatase and tensin homolog deleted from chromosome 10 (PTEN) mRNA expression in human airway epithelial cells Source: International Congress 2014 – Mechanistic studies of the airway epithelium Year: 2014 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 PUR1800 (RV1162), A novel narrow spectrum kinase inhibitor, but not Fluticasone, reduces TNFa-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Safety, tolerability and pharmacokinetics (PK) of single and repeat nebulised doses of a novel phosphoinositide 3-kinase Δ inhibitor (PI3KΔ), GSK2269557, administered to healthy male subjects in a phase I study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Identification of novel pathogenic mechanisms triggered by arginase activation in patients with COPD Source: International Congress 2016 – Airway response to infection Year: 2016 LATE-BREAKING ABSTRACT: Anti-inflammatory effect of RP6557, a dual PI3K d/? inhibitor, in glucocorticoid insensitive human neutrophils from chronic obstructive pulmonary disease patients Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Cigarette smoke extract (CSE) promotes acetylcholine (ACh) mediated inflammation and oxidative stress by PEBP1/Raf-mediated MEK and ERK pathway in human bronchial epithelial cells Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Targeting the mTOR signaling pathway to inhibit lung cell senescence in COPD Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Inhibition of phosphodiesterase 4B enhances glucocorticoid-dependent gene transcription in human airway epithelial cells: Implications for the treatment of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013